SELECT ISSUE

Revista Practica Medicala, Vol. X, Nr. 4 (42), 2015
ISSN 1842-8258  |  e-ISSN 2069-6108
ISSN-L 1842-8258

Indexed in / abstracted by

Thomson Reuters Embase
Scopus Cross-ref
Index Copernicus
Ulrichs Ebsco Host
Medline - Ebsco PubMed

HIGHLIGHTS

Publicarea de articole stiintifice

Stimati cititori, va reamintim ca autorii primi ai articolelor stiintifice pot acumula 80 de credite EMC in urma publicarii. Daca un articol are mai multi autori, cele 80 de credite [...]

Premiul Societatii pentru autori

Incepand cu 2016, Societatea Academica de Medicina a Familiei ofera Premiul Societatii - pentru autorii celor mai bune articole stiintifice publicate [...]

Plagiatul – in actualitate

Tema plagiatului este tot mai mult discutata in ultima vreme. Aparitia unor programe performante de cautare si identificare a similitudinilor intre texte [...]

Outcome in pediatric acute lymphoblastic leukemia in children and adolescents using contemporary protocols of chemotherapy – experience of a single Pediatric Hematology-Oncology Center

, , , , , and

ABSTRACT

The authors studied the outcome of a cohort of pediatric acute lymphoblastic leukemia (ALL) patients (33 children and adolescence) diagnosed and treated conforming to modern Chemotherapy Protocols (ALL ICBFM 2002, Interfant 06) in a single Center – Pediatric Clinic, Fundeni Clinical Institute, Bucharest, Romania.

They analyzed the factors which determine the prognosis and the outcome of these patients in the course of multi-agent systemic chemotherapy to stand at the base of these Protocols: initial age, initial leukocyte count, blasts immunophenotype, cytogenetic and molecular abnormalities, initial response to cortisone, risk groups, time to obtain the complet remission, etc. Among the factors they discussed, a great value was proven to have the minimal residual disease (MRD) determination in certain check points of Protocols and revaluation of patients risk conforming to MRD values.

Using the modern Protocols and continuously watching the evolution on therapy enable the authors to obtain results close to those of European and North American Pediatric Hematology Oncology Centers: OS 90.9% by 40 Mo and EFS 72.7% at the end of the same period of time.

Keywords: children and adolescents, acute lymphoblastic leukemia, prognosis, minimal residual disease

Full text | PDF

Leave a Reply